This article is more than 5 years old. Information may no longer be current.

Visunex receives FDA clearance for PanoCam LT imaging system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Visunex Medical Systems has received FDA clearance for the PanoCam LT wide-field digital imaging system for ocular imaging in newborns, the company announced in a press release.

The PanoCam LT is a compact, wireless imaging system designed to identify external, anterior segment and posterior segment defects that may have a long-term impact on the vision of children.

Currently, vision screening is not performed on most newborns in the U.S., but research has shown that one in 70 newborns may have some type of vision disorder, the release said.

“While many visual disorders may be transient, a growing number of clinicians believe that the screening of newborns may provide early detection of vision disorders, such as retinal hemorrhages, which may be a precursor to amblyopia. This serious vision disorder may have long-term effects or even permanently impair vision through adulthood,” the release said.

If retinal hemorrhages and other serious disorders are detected at birth, early therapeutic intervention may potentially prevent vision loss, according to the release.